

Thierry Calandra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8641605/publications.pdf>

Version: 2024-02-01

201
papers

47,714
citations

5574

82
h-index

2571

195
g-index

211
all docs

211
docs citations

211
times ranked

30193
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e1-611.e7.	6.0	3
2	High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure. <i>Intensive Care Medicine Experimental</i> , 2022, 10, 5.	1.9	13
3	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	7.2	19
4	COVID-19 rapidly increases MDSCs and prolongs innate immune dysfunctions. <i>European Journal of Immunology</i> , 2022, 52, 1676-1679.	2.9	9
5	Invasive Pulmonary Aspergillosis Goes Viral Again?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 275-277.	5.6	6
6	Macrophage migration inhibitory factor promotes the migration of dendritic cells through CD74 and the activation of the Src/PI3K/myosin II pathway. <i>FASEB Journal</i> , 2021, 35, e21418.	0.5	20
7	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	5.8	109
8	Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock. <i>Journal of Infection</i> , 2021, 82, 125-134.	3.3	22
9	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
10	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e049232.	1.9	10
11	Initial antimicrobial management of sepsis. <i>Critical Care</i> , 2021, 25, 307.	5.8	58
12	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 4888.	12.8	67
13	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab471.	0.9	15
14	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. <i>Mycoses</i> , 2021, 64, 1512-1520.	4.0	11
15	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
16	An Early Warning Score to predict ICU admission in COVID-19 positive patients. <i>Journal of Infection</i> , 2020, 81, 816-846.	3.3	13
17	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
18	Risk factors for candidemia: a prospective matched case-control study. <i>Critical Care</i> , 2020, 24, 109.	5.8	92

#	ARTICLE	IF	CITATIONS
19	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. Open Forum Infectious Diseases, 2020, 7, ofaa075.	0.9	26
20	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. Studies in Health Technology and Informatics, 2020, 270, 1163-1167.	0.3	3
21	Understanding and Enhancing Sepsis Survivorship. Priorities for Research and Practice. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 972-981.	5.6	96
22	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp>gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
23	Antimicrobial Therapy. , 2018, , 185-199.		0
24	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. Journal of Infection, 2018, 76, 489-495.	3.3	13
25	Changes in the epidemiological landscape of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2018, 73, i4-i13.	3.0	349
26	Rational approach in the management of Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases, 2018, 31, 578-586.	3.1	37
27	Antibiotics for Sepsisâ€”Finding the Equilibrium. JAMA - Journal of the American Medical Association, 2018, 320, 1433.	7.4	136
28	Let's add invasive aspergillosis to the list of influenza complications. Lancet Respiratory Medicine,the, 2018, 6, 733-735.	10.7	19
29	IRF5 Is a Key Regulator of Macrophage Response to Lipopolysaccharide in Newborns. Frontiers in Immunology, 2018, 9, 1597.	4.8	20
30	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. Haematologica, 2018, 103, e527-e530.	3.5	26
31	Prognostic value of quickSOFA as a predictor of 28-day mortality among febrile adult patients presenting to emergency departments in Dar es Salaam, Tanzania. PLoS ONE, 2018, 13, e0197982.	2.5	27
32	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Medicine, 2017, 43, 1225-1238.	8.2	123
33	Early diagnosis of invasive mould infections and disease. Journal of Antimicrobial Chemotherapy, 2017, 72, i19-i28.	3.0	87
34	Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and Candida albicans elimination. Gut Pathogens, 2017, 9, 9.	3.4	41
35	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3.5	468
36	Infections in the Cancer Patient. , 2017, , 723-738.e3.		2

#	ARTICLE	IF	CITATIONS
37	Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. <i>Frontiers in Immunology</i> , 2017, 8, 26.	4.8	29
38	Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2017, 25, 108.	2.6	96
39	Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3597-3602.	7.1	55
40	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016, 20, 125.	5.8	83
41	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	5.8	94
42	High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E997-1005.	7.1	67
43	Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis. <i>PLoS ONE</i> , 2016, 11, e0163542.	2.5	15
44	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. <i>Journal of Virology</i> , 2015, 89, 3819-3832.	3.4	10
45	Plant Immune Responses: Aphids Strike Back. <i>Current Biology</i> , 2015, 25, R604-R606.	3.9	3
46	Emerging single-cell technologies in immunology. <i>Journal of Leukocyte Biology</i> , 2015, 98, 23-32.	3.3	19
47	Sepsis: a roadmap for future research. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 581-614.	9.1	827
48	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. <i>Journal of Virology</i> , 2015, 89, 970-988.	3.4	30
49	Invasive candidiasis as a cause of sepsis in the critically ill patient. <i>Virulence</i> , 2014, 5, 161-169.	4.4	255
50	A revival for immunoglobulin therapy in septic shock?. <i>Intensive Care Medicine</i> , 2014, 40, 1957-1959.	8.2	0
51	What's new in antimicrobial use and resistance in critically ill patients?. <i>Intensive Care Medicine</i> , 2014, 40, 422-426.	8.2	6
52	Resistance of <i>Candida</i> spp. to antifungal drugs in the ICU: where are we now?. <i>Intensive Care Medicine</i> , 2014, 40, 1241-1255.	8.2	111
53	Polymorphisms in Tumor Necrosis Factor- α Increase Susceptibility to Intra-Abdominal <i>Candida</i> Infection in High-Risk Surgical ICU Patients*. <i>Critical Care Medicine</i> , 2014, 42, e304-e308.	0.9	17
54	β -Glucan Antigenemia Anticipates Diagnosis of Blood Culture-Negative Intraabdominal Candidiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1100-1109.	5.6	183

#	ARTICLE	IF	CITATIONS
55	Lack of <i>Mycobacterium tuberculosis</i> “specific interleukin-17A”-producing CD4 ⁺ T cells in active disease. <i>European Journal of Immunology</i> , 2013, 43, 939-948.	2.9	60
56	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013, 210, 1109-1116.	8.5	193
57	Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy”EORTC Infectious Diseases Group Trial XV. <i>Journal of Clinical Oncology</i> , 2013, 31, 1149-1156.	1.6	72
58	Impact of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry on the Clinical Management of Patients With Gram-negative Bacteremia: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 1101-1107.	5.8	197
59	Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 137-149.	3.1	36
60	Macrophage Migration Inhibitory Factor Deficiency Is Associated With Impaired Killing of Gram-Negative Bacteria by Macrophages and Increased Susceptibility to <i>Klebsiella pneumoniae</i> Sepsis. <i>Journal of Infectious Diseases</i> , 2013, 207, 331-339.	4.0	71
61	Host Innate Immune Responses to Microbial Pathogens. <i>Current Vascular Pharmacology</i> , 2013, 11, 123-132.	1.7	1
62	Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C. <i>PLoS ONE</i> , 2013, 8, e74831.	2.5	25
63	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. <i>FASEB Journal</i> , 2012, 26, 907-916.	0.5	50
64	Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β -Sheet Structure of MIF. <i>Journal of Biological Chemistry</i> , 2012, 287, 7446-7455.	3.4	50
65	Epigenetic Control of MIF Expression. , 2012, , 121-137.		0
66	Sepsis studies need new direction. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 503-505.	9.1	111
67	Species-Specific Recognition of <i>Aspergillus fumigatus</i> by Toll-like Receptor 1 and Toll-like Receptor 6. <i>Journal of Infectious Diseases</i> , 2012, 205, 944-954.	4.0	48
68	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. <i>Cytokine</i> , 2012, 60, 338-340.	3.2	21
69	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2012, 55, 381-390.	5.8	178
70	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. <i>PLoS ONE</i> , 2012, 7, e35485.	2.5	30
71	Modulation of human memory T cell function by different antigen-presenting cells. <i>European Journal of Immunology</i> , 2012, 42, 799-802.	2.9	3
72	Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. <i>Critical Care</i> , 2012, 16, R114.	5.8	44

#	ARTICLE	IF	CITATIONS
73	Invasive Candida infections in the ICU. <i>Mycoses</i> , 2012, 55, 65-72.	4.0	8
74	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. <i>PLoS ONE</i> , 2012, 7, e48524.	2.5	30
75	Histone Deacetylase Inhibitors Impair Antibacterial Defenses of Macrophages. <i>Journal of Infectious Diseases</i> , 2011, 204, 1367-1374.	4.0	83
76	Monitoring Procalcitonin in Febrile Neutropenia: What Is Its Utility for Initial Diagnosis of Infection and Reassessment in Persistent Fever?. <i>PLoS ONE</i> , 2011, 6, e18886.	2.5	39
77	Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. <i>Blood</i> , 2011, 117, 1205-1217.	1.4	311
78	Dominant TNF- α + Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011, 17, 372-376.	30.7	380
79	Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 248-256.	5.8	114
80	Estradiol and Progesterone Strongly Inhibit the Innate Immune Response of Mononuclear Cells in Newborns. <i>Infection and Immunity</i> , 2011, 79, 2690-2698.	2.2	107
81	A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses. <i>PLoS ONE</i> , 2011, 6, e24244.	2.5	67
82	Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?. <i>Current Opinion in Critical Care</i> , 2010, 16, 442-444.	3.2	6
83	Interleukin-33 safeguards neutrophils in sepsis. <i>Nature Medicine</i> , 2010, 16, 638-639.	30.7	9
84	Role of MyD88 and Toll-Like Receptors 2 and 4 in the Sensing of <i>Parachlamydia acanthamoebae</i> . <i>Infection and Immunity</i> , 2010, 78, 5195-5201.	2.2	16
85	Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. <i>Journal of Endocrinology</i> , 2010, 206, 297-306.	2.6	30
86	Identification and Characterization of Novel Classes of Macrophage Migration Inhibitory Factor (MIF) Inhibitors with Distinct Mechanisms of Action. <i>Journal of Biological Chemistry</i> , 2010, 285, 26581-26598.	3.4	80
87	Expression and Function of Macrophage Migration Inhibitory Factor (MIF) in Melioidosis. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e605.	3.0	17
88	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. <i>Critical Care</i> , 2010, 14, R222.	5.8	250
89	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- <i>N</i> -Oxide, Anidulafungin, and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> . 2010. 54. 5303-5315.	3.2	108
90	Infections in the neutropenic cancer patient. , 2010, , 804-820.		0

#	ARTICLE	IF	CITATIONS
91	Invasive mould infections: a multi-disciplinary update. <i>Medical Mycology</i> , 2009, 47, 571-583.	0.7	21
92	A New Step toward Individualized Antifungal Prevention in Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2009, 49, 733-735.	5.8	6
93	TLR2-mediated neutrophil depletion exacerbates bacterial sepsis: Fig. 1.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6889-6890.	7.1	9
94	Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2348-2352.	7.1	252
95	Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome. <i>PLoS Pathogens</i> , 2009, 5, e1000480.	4.7	285
96	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 665-667.	3.0	6
97	Antibiotic Usage and Resistance. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2367.	7.4	32
98	Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1749-1758.	4.1	48
99	Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. <i>Intensive Care Medicine</i> , 2009, 35, 903-908.	8.2	62
100	Glucocorticoid-induced MIF expression by human CEM T cells. <i>Cytokine</i> , 2009, 48, 177-185.	3.2	31
101	Histoplasma capsulatum var. duboisii infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 85-89.	1.8	16
102	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 386-388.	2.5	15
103	A New Class of Isothiocyanate-Based Irreversible Inhibitors of Macrophage Migration Inhibitory Factor. <i>Biochemistry</i> , 2009, 48, 9858-9870.	2.5	51
104	Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. <i>Critical Care Medicine</i> , 2009, 37, 2929-2938.	0.9	140
105	Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. <i>Intensive Care Medicine</i> , 2008, 34, 17-60.	8.2	2,078
106	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	5.8	4,375
107	Bench-to-bedside review: Candida infections in the intensive care unit. <i>Critical Care</i> , 2008, 12, 204.	5.8	174
108	Fully human anti-macrophage migration inhibitory factor antibodies as potential therapeutics for sepsis and septic shock. <i>Critical Care</i> , 2008, 12, P15.	5.8	0

#	ARTICLE	IF	CITATIONS
109	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	5.8	368
110	Reply to Pasqualotto and Sukiennik. <i>Clinical Infectious Diseases</i> , 2008, 47, 293-294.	5.8	0
111	1,3- β -D-Glucan Antigenemia for Early Diagnosis of Invasive Fungal Infections in Neutropenic Patients with Acute Leukemia. <i>Clinical Infectious Diseases</i> , 2008, 46, 878-885.	5.8	254
112	<i>Candida</i> Arteritis in Patients Who Have Not Received Organ Transplants: Case Report and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2008, 46, e106-e111.	5.8	14
113	Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes. <i>Clinical Infectious Diseases</i> , 2008, 46, 201-211.	5.8	823
114	Antifungals in the ICU. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 610-619.	3.1	36
115	The Role of Macrophage Migration Inhibitory Factor in Mouse Islet Transplantation. <i>Transplantation</i> , 2008, 86, 1361-1369.	1.0	20
116	Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. <i>Critical Care Medicine</i> , 2008, 36, 296-327.	0.9	7,331
117	Sepsis: Time to reconsider the concept. <i>Critical Care Medicine</i> , 2008, 36, 964-966.	0.9	107
118	Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor. <i>Journal of Biological Chemistry</i> , 2007, 282, 29910-29918.	3.4	97
119	MIF in Innate Immunity and Infectious Diseases. , 2007, , 107-132.		0
120	Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 137-143.	3.2	94
121	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. <i>Aids</i> , 2007, 21, 441-446.	2.2	139
122	Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1321-1328.	5.8	98
123	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. <i>Shock</i> , 2007, 27, 482-487.	2.1	29
124	Exhaustion is Associated With Low Macrophage Migration Inhibitory Factor Expression in Patients With Coronary Artery Disease. <i>Psychosomatic Medicine</i> , 2007, 69, 68-73.	2.0	9
125	Innate immunogenetics: a tool for exploring new frontiers of host defence. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 531-542.	9.1	76
126	The need for aminoglycosides in combination with β -lactams for high-risk, febrile neutropaenic patients with leukaemia. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 13-22.	2.2	20

#	ARTICLE	IF	CITATIONS
127	Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. European Journal of Cancer, Supplement, 2007, 5, 32-42.	2.2	51
128	The Macrophage Migration Inhibitory Factor-Glucocorticoid Dyad: Regulation of Inflammation and Immunity. Molecular Endocrinology, 2007, 21, 1267-1280.	3.7	232
129	Regulation of constitutive and microbial pathogen-induced human <i>macrophage migration inhibitory factor</i> (MIF) <i>gene expression. European Journal of Immunology, 2007, 37, 3509-3521.	2.9	59
130	Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. Journal of Mass Spectrometry, 2007, 42, 440-449.	1.6	20
131	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. Clinical Immunology, 2007, 123, 60-65.	3.2	13
132	Gas6 and Its Receptors Are Implicated in Sepsis as Modulators of Innate Immunity.. Blood, 2007, 110, 2409-2409.	1.4	0
133	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine, 2006, 36, 51-56.	3.2	31
134	Cytokines and <i>Escherichia coli</i> Sepsis. EcoSal Plus, 2006, 2, .	5.4	4
135	Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BMC Infectious Diseases, 2006, 6, 9.	2.9	73
136	Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cellular Signalling, 2006, 18, 688-703.	3.6	177
137	Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Critical Care Medicine, 2005, 33, 1708-1716.	0.9	131
138	Changing face of health-care associated fungal infections. Current Opinion in Infectious Diseases, 2005, 18, 314-319.	3.1	37
139	The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Critical Care Medicine, 2005, 33, 1538-1548.	0.9	714
140	Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. European Journal of Immunology, 2005, 35, 3405-3413.	2.9	174
141	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis and Rheumatism, 2005, 52, 3020-3029.	6.7	203
142	Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Medicine, 2005, 31, 1514-1521.	8.2	30
143	Coxiella burnetii vascular graft infection. BMC Infectious Diseases, 2005, 5, 109.	2.9	24
144	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer. Clinical Infectious Diseases, 2005, 40, 239-245.	5.8	56

#	ARTICLE	IF	CITATIONS
145	Macrophage Migration Inhibitory Factor: Gene Polymorphisms and Susceptibility to Inflammatory Diseases. <i>Clinical Infectious Diseases</i> , 2005, 41, S513-S519.	5.8	119
146	Macrophage Migration Inhibitory Factor Reduces the Growth of Virulent <i>Mycobacterium tuberculosis</i> in Human Macrophages. <i>Infection and Immunity</i> , 2005, 73, 3783-3786.	2.2	45
147	Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (<i>Tlr4</i>) gene expression. <i>Biochemical Journal</i> , 2005, 387, 355-365.	3.7	78
148	Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 95-101.	1.8	96
149	Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991â€“2000. <i>Clinical Infectious Diseases</i> , 2004, 38, 311-320.	5.8	401
150	Clinical Trials of Antifungal Prophylaxis among Patients Undergoing Surgery. <i>Clinical Infectious Diseases</i> , 2004, 39, S185-S192.	5.8	42
151	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Intensive Care Medicine</i> , 2004, 30, 536-555.	8.2	2,079
152	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Critical Care Medicine</i> , 2004, 32, 858-873.	0.9	4,598
153	Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. <i>Critical Care Medicine</i> , 2004, 32, S495-S512.	0.9	172
154	Response to van Saene et al.'s comment on "Prevention of severe <i>Candida</i> infections in non-neutropenic, high-risk, critically ill patients". <i>Intensive Care Medicine</i> , 2003, 29, 1196-1196.	8.2	0
155	Macrophage migration inhibitory factor: a regulator of innate immunity. <i>Nature Reviews Immunology</i> , 2003, 3, 791-800.	22.7	2,045
156	Science, medicine, and the future: Pathogenesis of sepsis: new concepts and implications for future treatment. <i>BMJ: British Medical Journal</i> , 2003, 326, 262-266.	2.3	171
157	Macrophage Migration Inhibitory Factor and Host Innate Immune Responses to Microbes. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 573-576.	1.5	77
158	Macrophage Migration Inhibitory Factor and Host Innate Immune Defenses against Bacterial Sepsis. <i>Journal of Infectious Diseases</i> , 2003, 187, S385-S390.	4.0	71
159	Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). <i>Journal of Endotoxin Research</i> , 2003, 9, 119-123.	2.5	53
160	2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2002, 34, 730-751.	5.8	1,738
161	Infections in neutropenic cancer patients. <i>Lancet, The</i> , 2002, 359, 723-725.	13.7	39
162	The Generation of Inflammatory Responses. , 2002, , 687-727.		2

#	ARTICLE	IF	CITATIONS
163	Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock. , 2002, , 539-558.		2
164	Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes and Infection, 2002, 4, 449-460.	1.9	314
165	Antifungal prophylaxis for intensive care unit patients: let's fine tune it. Intensive Care Medicine, 2002, 28, 1698-1700.	8.2	17
166	Cytokines in septic shock. Current Clinical Topics in Infectious Diseases, 2002, 22, 1-23.	0.3	12
167	Antibiotics in sepsis. Intensive Care Medicine, 2001, 27, S33-S48.	8.2	126
168	Clinical expert round table discussion (session 1) at the Margaux Conference on Critical Illness: Innate immunity: Host recognition of and sensitivity to bacterial components. Critical Care Medicine, 2001, 29, S19-S20.	0.9	1
169	New strategies for clinical trials in patients with sepsis and septic shock. Critical Care Medicine, 2001, 29, 880-886.	0.9	157
170	Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Critical Care Medicine, 2001, 29, S13-S15.	0.9	68
171	MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature, 2001, 414, 920-924.	27.8	537
172	Critical Role of Lipopolysaccharide-Binding Protein and CD14 in Immune Responses against Gram-Negative Bacteria. Journal of Immunology, 2001, 167, 2759-2765.	0.8	103
173	Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin. Infection and Immunity, 2001, 69, 378-385.	2.2	32
174	Macrophage Migration Inhibitory Factor (MIF): A Pro-Inflammatory Mediator of Sepsis. Perspectives on Critical Care Infectious Diseases, 2001, , 45-67.	0.1	2
175	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). British Journal of Haematology, 2000, 109, 396-404.	2.5	7
176	Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine, 2000, 6, 164-170.	30.7	709
177	Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature, 2000, 408, 211-216.	27.8	539
178	Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of Plasmodium chabaudi -Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial Anemia. Infection and Immunity, 2000, 68, 2259-2267.	2.2	120
179	The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. Journal of Clinical Investigation, 2000, 106, 1291-1300.	8.2	127
180	Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. New England Journal of Medicine, 1999, 341, 312-318.	27.0	360

#	ARTICLE	IF	CITATIONS
181	A role for the endocrine and pro-inflammatory mediator MIF in the control of insulin secretion during stress. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 47-54.	4.0	33
182	Treatment of Sepsis. <i>Drugs</i> , 1999, 57, 127-132.	10.9	43
183	Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. <i>Critical Care Medicine</i> , 1999, 27, 1066-1072.	0.9	433
184	Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. <i>Journal of Molecular Medicine</i> , 1998, 76, 151-161.	3.9	153
185	Molecular basis of host-pathogen interaction in septic shock. <i>Current Opinion in Microbiology</i> , 1998, 1, 49-55.	5.1	89
186	Transcriptional Activation of the Macrophage Migration-Inhibitory Factor Gene by the Corticotropin-Releasing Factor is Mediated by the Cyclic Adenosine 3',5'-Monophosphate Responsive Element-Binding Protein CREB in Pituitary Cells. <i>Molecular Endocrinology</i> , 1998, 12, 698-705.	3.7	51
187	Monocyte deactivation in septic shock. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 279-284.	3.1	16
188	Biochemical and Mutational Investigations of the Enzymatic Activity of Macrophage Migration Inhibitory Factor. <i>Biochemistry</i> , 1997, 36, 15356-15362.	2.5	149
189	Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System. <i>Critical Reviews in Immunology</i> , 1997, 17, 77-88.	0.5	186
190	MIF as a glucocorticoid-induced modulator of cytokine production. <i>Nature</i> , 1995, 377, 68-71.	27.8	1,113
191	Localization of Macrophage Migration Inhibitory Factor (MIF) to Secretory Granules within the Corticotrophic and Thyrotrophic Cells of the Pituitary Gland. <i>Molecular Medicine</i> , 1995, 1, 781-788.	4.4	170
192	Escherichia coli Resistant to Fluoroquinolones in Patients with Cancer and Neutropenia. <i>New England Journal of Medicine</i> , 1994, 330, 1240-1241.	27.0	195
193	The emerging role of MIF in septic shock and infection. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1994, 8, 123-127.	0.7	47
194	Bacteremia due to viridans streptococci in neutropenic patients: A review. <i>American Journal of Medicine</i> , 1994, 97, 256-264.	1.5	285
195	Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. <i>Trends in Microbiology</i> , 1994, 2, 198-201.	7.7	45
196	Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF). <i>Biochemistry</i> , 1994, 33, 14144-14155.	2.5	405
197	High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. <i>American Journal of Medicine</i> , 1991, 91, 23-29.	1.5	578
198	Cytokines and septic shock. <i>Diagnostic Microbiology and Infectious Disease</i> , 1990, 13, 377-381.	1.8	29

#	ARTICLE	IF	CITATIONS
199	CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTS. Lancet, The, 1989, 334, 1437-1440.	13.7	213
200	Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock. Thrombosis and Haemostasis, 1989, 61, 459-462.	3.4	186
201	Ceftazidime Combined with a Short or Long Course of Amikacin for Empirical Therapy of Gram-Negative Bacteremia in Cancer Patients with Granulocytopenia. New England Journal of Medicine, 1987, 317, 1692-1698.	27.0	368